HSP90AA1 and cancer: In this light, disabling of HSP90 cancer networks in their multiple subcellular compartments, mitochondrial and cytosolic, by our peptidic inhibitors, may cause irreversible collapse of mitochondria, degradation of HSP90 client proteins in the cytosol, and tumour cell killing by apoptosis and/or autophagy, thus favoring the action of both cDDP and RTX.